INVESTOR RELATION

Zhejiang Jianfeng Pharmaceutical Co., Ltd. ("Jianfeng Pharmaceutical") is a subsidiary of Zhejiang Jianfeng Group Co., Ltd. (stock code: 600668, "Jianfeng Group"), a listed company. Mr. Jiang Xiaomeng, a director of HebaBiz, is nomiated by Jianfeng Group. He is currently the Chairman of Jianfeng Group, Secretary of the Party Committee, and Vice Chairman of the board of Tasly Group and Vice Chairman of Tasly Pharmaceutical Group Co., Ltd. Jianfeng Group is a significant shareholder of Tasly Holding Group Limited ("Tasly Group"). Tasly Group is the controlling shareholder of Tasly Pharmaceutical Group Co., Ltd., a pioneer of Chinese traditional medicine modernization, listed on the Shanghai Stock Exchange (stock code: 600535).

Zhongbo Juli (Beijing) Investment Management Co., Ltd. ("ZBJL Capital") is a private equity investment institution established in 2013. Its main investment direction is new-generation information technology, biomedicine and new energy. Adhering to the investment philosophy of "Based on science and technology, realising value", ZBJL Capital focuses on scientific and technological innovation and human health, actively excavates investment targets that can become great enterprises on the cutting edge science and technology track, empowers them with both capital and resources, helps the development of Chinese science and technology enterprises, creates value and benefits mankind and society. ZBJL Capital attaches more importance to innovation and significant clinical significance as part of their key layout in the biomedicine track, does not blindly follow the trend, and constantly explores potential unicorn enterprises with high technical barriers and strong core competitiveness.